Issue 2, 2017

Synthesis and biological evaluation of (−)-kunstleramide and its derivatives

Abstract

Stereoselective total synthesis of (−)-kunstleramide, a cytotoxic dienamide from the bark of Beilschmiedia kunstleri gamble, has been accomplished by using Keck's asymmetric allylation and Trost isomerization as key reactions. Application of the developed strategy for the synthesis of a series of amide analogues (8–22) was also reported. Furthermore, the synthesized compounds were evaluated for their in vitro anti-proliferative activities against human epithelial lung carcinoma (A549), human epithelial cervical cancer (HeLa), human breast adenocarcinoma (MCF7) and human neuroblastoma (IMR32) cell lines using the SRB assay. All the compounds show moderate anti-proliferative activity against all cell lines. Some of the piperazine derivatives (17–22) strongly inhibit the growth of breast cancer cells with IC50 values of 8–20 μM.

Graphical abstract: Synthesis and biological evaluation of (−)-kunstleramide and its derivatives

Supplementary files

Article information

Article type
Research Article
Submitted
02 Nov 2016
Accepted
08 Dec 2016
First published
09 Dec 2016

Med. Chem. Commun., 2017,8, 394-404

Synthesis and biological evaluation of (−)-kunstleramide and its derivatives

R. Venkateshwarlu, B. Chinnababu, U. Ramulu, K. Purushotham Reddy, M. Damoder Reddy, P. Sowjanya, P. Venkateswara Rao and S. Aravind, Med. Chem. Commun., 2017, 8, 394 DOI: 10.1039/C6MD00606J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements